Osimertinib-Induced Cardiomyopathy

Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Shruti R., Brown, Sherry-Ann N., Kubusek, Jilan E., Mansfield, Aaron S., Duma, Narjust
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298525/
https://www.ncbi.nlm.nih.gov/pubmed/34317311
http://dx.doi.org/10.1016/j.jaccas.2019.12.038
_version_ 1783726083804233728
author Patel, Shruti R.
Brown, Sherry-Ann N.
Kubusek, Jilan E.
Mansfield, Aaron S.
Duma, Narjust
author_facet Patel, Shruti R.
Brown, Sherry-Ann N.
Kubusek, Jilan E.
Mansfield, Aaron S.
Duma, Narjust
author_sort Patel, Shruti R.
collection PubMed
description Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib is reversible and occurs at a dose of 80 mg/day. (Level of Difficulty: Intermediate.)
format Online
Article
Text
id pubmed-8298525
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-82985252021-07-26 Osimertinib-Induced Cardiomyopathy Patel, Shruti R. Brown, Sherry-Ann N. Kubusek, Jilan E. Mansfield, Aaron S. Duma, Narjust JACC Case Rep Case Report Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib is reversible and occurs at a dose of 80 mg/day. (Level of Difficulty: Intermediate.) Elsevier 2020-04-01 /pmc/articles/PMC8298525/ /pubmed/34317311 http://dx.doi.org/10.1016/j.jaccas.2019.12.038 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Patel, Shruti R.
Brown, Sherry-Ann N.
Kubusek, Jilan E.
Mansfield, Aaron S.
Duma, Narjust
Osimertinib-Induced Cardiomyopathy
title Osimertinib-Induced Cardiomyopathy
title_full Osimertinib-Induced Cardiomyopathy
title_fullStr Osimertinib-Induced Cardiomyopathy
title_full_unstemmed Osimertinib-Induced Cardiomyopathy
title_short Osimertinib-Induced Cardiomyopathy
title_sort osimertinib-induced cardiomyopathy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298525/
https://www.ncbi.nlm.nih.gov/pubmed/34317311
http://dx.doi.org/10.1016/j.jaccas.2019.12.038
work_keys_str_mv AT patelshrutir osimertinibinducedcardiomyopathy
AT brownsherryannn osimertinibinducedcardiomyopathy
AT kubusekjilane osimertinibinducedcardiomyopathy
AT mansfieldaarons osimertinibinducedcardiomyopathy
AT dumanarjust osimertinibinducedcardiomyopathy

Ejemplares similares